Regeneron Q2 revenue up 163% to $5.14B; GAAP EPS $27.97; EYLEA sales record $1.42B

REGENERON PHARMACEUTICALS, INC.

2021-Q2 EPS reported $38.07 revenue$7,667,200,000

Total revenues $5.14B (+163% YoY) including $2.59B REGEN-COV; core revenue ex-REGEN-COV +22%.
GAAP diluted EPS $27.97 vs $7.61 in Q2 2020; non-GAAP diluted EPS $25.80 vs $7.16.
EYLEA US net sales record $1.42B (+28% YoY); Dupixent global net sales $1.50B (+59% YoY, recorded by Sanofi).
REGEN-COV: $2.59B US sales from 1.25M doses; EUA expanded for prophylaxis; Japan full approval; RECOVERY trial showed 20% mortality reduction in seronegative.
Pipeline: Dupixent Phase 3 CSU positive; Libtayo Phase 3 NSCLC stopped early for survival benefit; $1.8B Tarrytown campus expansion over 6 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.